Improving Aggregate Removal To Enhance Clinical Manufacturing of mAbs
White Paper Mar 18, 2021
Over the past two decades, monoclonal antibodies (mAbs) have been one of the most dominant segments of the biotherapeutics market. Ensuring mAbs’ safety and efficacy is vital but is made complicated by the fact that antibodies can have a tendency to aggregate during production, decreasing efficacy and increasing the risk of immunogenicity.
Download this whitepaper to discover a hydrophobic interaction chromatography flow-through method that:
- Improves both processes efficiency and productivity
- Allows for process simplification and increased throughput
- Provides an alternate purification option for mAb development
Related White Papers
Single-cell sequencing is quickly becoming a standard tool in biological research due to the scale and depth of insight it provides across diverse cell populations. The pharmaceutical industry is exploiting single-cell approaches to identify novel therapeutic targets and accelerate promising assets through development.
READ MOREAccess this whitepaper to discover a system that performs virtual screening at ultra-high-throughput scale, requires minimal costs and can be run with cloud computing or HPC resources.
READ MOREThe rapid and cost-effective production of conventional monoclonal antibodies (mAbs) for clinical trials has contributed toward their wide adoption. As the number of next-generation antibody-based candidates with modified or absent Fc domains increases, biomanufacturers face a need to establish alternative affinity purification technologies.
READ MORELike what you just read? You can find similar content on the communities below.
Analysis & Separations Cell Science Immunology & MicrobiologyTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE
